Phosphodiesterase 11 A (PDE11A), a potential biomarker for glioblastoma.

IF 1.6 4区医学 Q4 TOXICOLOGY

Toxicological Research Pub Date : 2022-07-01 DOI:10.1007/s43188-022-00129-1

Hyunji Lee, Sungjin Park, Gyeyeong Kong, So Hee Kwon, Jisoo Park, Jongsun Park, Seon-Hwan Kim

{"title":"Phosphodiesterase 11 A (PDE11A), a potential biomarker for glioblastoma.","authors":"Hyunji Lee, Sungjin Park, Gyeyeong Kong, So Hee Kwon, Jisoo Park, Jongsun Park, Seon-Hwan Kim","doi":"10.1007/s43188-022-00129-1","DOIUrl":null,"url":null,"abstract":"<p><p>Phosphodiesterase 11A (PDE11A), a 3',5'-cyclic nucleotide phosphodiesterase, is a key regulator of intracellular signaling that functions by degrading cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). However, the function of PDE11A in brain tumors is currently unclear. In this study, we found that PDE11A may be involved in glioblastoma development. The protein and mRNA levels of PDE11A were significantly higher in U87-MG, U251-MG and U343-MG glioblastoma cell lines. Gene expression analyses by deep-sequencing revealed that PDE11A mRNA levels were higher in U87-MG and U251-MG cells compared to other cells in the cerebral cortex. A comprehensive analysis of The Cancer Genome Atlas (TCGA) data revealed that PDE11A expression was also elevated in glioblastoma patients. Taken together, these data indicate that PDE11A expression was increased in glioblastoma cell lines and glioma patients, suggesting that PDE11A could be a putative diagnostic marker and therapeutic target for glioma.</p>","PeriodicalId":23181,"journal":{"name":"Toxicological Research","volume":"38 3","pages":"409-415"},"PeriodicalIF":1.6000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247127/pdf/43188_2022_Article_129.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxicological Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43188-022-00129-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"TOXICOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Phosphodiesterase 11A (PDE11A), a 3',5'-cyclic nucleotide phosphodiesterase, is a key regulator of intracellular signaling that functions by degrading cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). However, the function of PDE11A in brain tumors is currently unclear. In this study, we found that PDE11A may be involved in glioblastoma development. The protein and mRNA levels of PDE11A were significantly higher in U87-MG, U251-MG and U343-MG glioblastoma cell lines. Gene expression analyses by deep-sequencing revealed that PDE11A mRNA levels were higher in U87-MG and U251-MG cells compared to other cells in the cerebral cortex. A comprehensive analysis of The Cancer Genome Atlas (TCGA) data revealed that PDE11A expression was also elevated in glioblastoma patients. Taken together, these data indicate that PDE11A expression was increased in glioblastoma cell lines and glioma patients, suggesting that PDE11A could be a putative diagnostic marker and therapeutic target for glioma.

Abstract Image

查看原文本刊更多论文

磷脂二酯酶11a (PDE11A)，胶质母细胞瘤的潜在生物标志物。

磷酸二酯酶11A (PDE11A)是一种3'，5'-环核苷酸磷酸二酯酶，是细胞内信号转导的关键调控因子，通过降解环磷酸腺苷(cAMP)和环鸟苷(cGMP)发挥作用。然而，PDE11A在脑肿瘤中的功能目前尚不清楚。在本研究中，我们发现PDE11A可能参与了胶质母细胞瘤的发展。在U87-MG、U251-MG和U343-MG胶质母细胞瘤细胞系中PDE11A蛋白和mRNA水平均显著升高。基因表达深度测序分析显示，与大脑皮层其他细胞相比，U87-MG和U251-MG细胞中的PDE11A mRNA水平较高。对癌症基因组图谱(TCGA)数据的综合分析显示，PDE11A在胶质母细胞瘤患者中的表达也升高。综上所述，这些数据表明PDE11A在胶质母细胞瘤细胞系和胶质瘤患者中的表达增加，提示PDE11A可能是胶质瘤的推定诊断标志物和治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Toxicological Research TOXICOLOGY-

CiteScore

4.20

自引率

4.30%

发文量

期刊介绍： Toxicological Research is the official journal of the Korean Society of Toxicology. The journal covers all areas of Toxicological Research of chemicals, drugs and environmental agents affecting human and animals, which in turn impact public health. The journal’s mission is to disseminate scientific and technical information on diverse areas of toxicological research. Contributions by toxicologists, molecular biologists, geneticists, biochemists, pharmacologists, clinical researchers and epidemiologists with a global view on public health through toxicological research are welcome. Emphasis will be given to articles providing an understanding of the toxicological mechanisms affecting animal, human and public health. In the case of research articles using natural extracts, detailed information with respect to the origin, extraction method, chemical profiles, and characterization of standard compounds to ensure the reproducible pharmacological activity should be provided.